Abstract
BACKGROUND: SARS-CoV-2 outbreaks remains a medical and economic challenge, due to the lack of a suitable drug or vaccine. The glycan in some proteins plays an important role in protein folding, sorting, transport, and oligomerization, so the hindering of N-linked glycosylation of glycoproteins will prevent assembly of the virion. Tunicamycin anticancer drug inhibits the N- linked glycan.
 AIM: This study aimed to find out the mechanism action of tunicamycin on the viral glycoproteins.
 RESULTS: The growth of the virus in the presence of tunicamycin conducted in the production of non-infectious and absence of spike protein (spikeless virions). Tunicamycin inhibits E2, S, and M glycoproteins of coronaviruses. Tunicamycin has also diminished glycosylation of PTMs such as HE, and 8ab of SARS-CoV. Finally,
 CONCLUSION: This study recommends using this drug to treat the SARS-CoV-2.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Open Access Macedonian Journal of Medical Sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
